B
Bull
Bull · 25%ZYBT
$7.95
Szenariopreis
$1.730
-0.029 (-1.70%)Zum Schluss
Loading chart…
- High
- 1.810
- Open
- 1.810
- VWAP
- 1.73
- Vol
- 37.43K
- Mkt Cap
- —
- Low
- 1.660
- Amount
- 64.88K
- EV/EBITDA, TTM
- 0.00
Zhengye Biotechnology Holding Ltd is a company mainly engaged in the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. The Company markets a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The Company owns about 44 veterinary vaccines in its product portfolio, which cover veterinary vaccines for livestock, including monovalent vaccine, polyvalent vaccine, combined vaccine and combined and polyvalent vaccine. The Company also engages in vaccines for treating livestock. The Company mainly conducts its business in the domestic market. The Company mainly conducts its business in the domestic and overseas market.
AI analysis of Zhengye Biotechnology Holding Ltd (ZYBT)
holdZhengye Biotechnology Holding Limited is not a good buy right now due to significant volatility and recent performance issues. The stock has seen a drastic 15.20% decline over the past five days and an 86.34% drop over the past year, indicating instability. Although the company regained Nasdaq compliance, it reported a GAAP EPS of -0.21, reflecting ongoing profitability challenges. The current price is $1.73, and with an RSI of 44.247, it suggests the stock is neither overbought nor oversold, but caution is advised given the potential for further declines.
Bewertungskennzahlen
The current forward P/E ratio for Zhengye Biotechnology Holding Ltd (ZYBT) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for ZYBT
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
8.508-06seekingalphaZhengye Biotechnology Regains Nasdaq Compliance
2.007-21NewsfilterZhengye Biotechnology Responds to Unusual Trading Activity
2.007-21NASDAQ.COMZhengye Biotechnology Shares Surge, Easing Delisting Concerns
- 9.504-28seekingalpha
Zhengye Biotechnology Reports FY Financials
9.504-28PRnewswireZhengye Biotechnology Reports FY 2025 Financial Results Amid Market Challenges
ZYBT FAQ — answered by Alphio AI
Zhengye Biotechnology Holding Ltd is a company mainly engaged in the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. The Company markets a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The Company owns about 44 veterinary vaccines in its product portfolio, which cover veterinary vaccines for livestock, including monovalent vaccine, polyvalent vaccine, combined vaccine and combined and polyvalent vaccine. The Company also engages in vaccines for treating livestock. The Company mainly conducts its business in the domestic market. The Company mainly conducts its business in the domestic and overseas market. It operates in the Healthcare sector.
Zhengye Biotechnology Holding Limited is not a good buy right now due to significant volatility and recent performance issues. The stock has seen a drastic 15.20% decline over the past five days and an 86.34% drop over the past year, indicating instability. Although the company regained Nasdaq compliance, it reported a GAAP EPS of -0.21, reflecting ongoing profitability challenges. The current price is $1.73, and with an RSI of 44.247, it suggests the stock is neither overbought nor oversold, but caution is advised given the potential for further declines.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.